Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111564 · ClinicalTrials.gov registry record · Phase 3
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,024
- Enrollment target
NCT02111564: Completed Phase 3 study, sponsored by Janssen Research & Development.
NCT02111564 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 12,024 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1460% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02111564, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,024 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
Primary Outcome
Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45.
Interventions
- DRUG Placebo
- DRUG Rivaroxaban, 10 mg
- DRUG Rivaroxaban, 7.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,024 participants |
| Start Date | 2014-01-07 |
| Est. Completion | 2018-05-03 |
| Phase | Phase 3 |
What the finished NCT02111564 record still lists
NCT02111564 is an interventional study that assigns participants to a tested intervention. Its 12,024 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1460% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02111564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02111564 about?
NCT02111564 is a clinical study titled "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients". The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.
What is the current status of trial NCT02111564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,024 participants. The study started on 2014-01-07. Estimated completion is 2018-05-03.
What interventions are being tested in trial NCT02111564?
The interventions under investigation include: Placebo (DRUG), Rivaroxaban, 10 mg (DRUG), Rivaroxaban, 7.5 mg (DRUG).
Who is sponsoring clinical trial NCT02111564?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02111564's enrollment target sits among peer trials
12,024 20th of 2000 higher than 1,981 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI